Impact of the COVID-19 Pandemic on a Clinical Trial: A Quantitative Report on Study Engagement and Strategies

Shaaron E Brown1, Meagan Miller, Jodi Darring

  • 1Departments of Physical Therapy (Drs Brown and Shall and Ms Miller) and Neurology (Dr Harper), Virginia Commonwealth University, Richmond, Virginia; Rehabilitation and Movement Science Program (Dr Brown and Ms Inamdar), Department of Physical Therapy, Virginia Commonwealth University, Richmond, Virginia; University of Virginia Children's Hospital (Ms Darring and Dr Hyde), Charlottesville, Virginia; Division of Physical Therapy (Dr Inamdar), School of Medicine, West Virginia University, Morgantown, West Virginia; Division of Biokinesiology and Physical Therapy (Ms Salgaonkar and Dr Dusing), University of Southern California, Los Angeles, California; Division of Neonatology (Dr Burnsed), University of Virginia, Charlottesville, Virginia; Neuro-Developmental and Behavioral Pediatrics (Dr Stevenson), University of Virginia School of Medicine, Charlottesville, Virginia; Division of Neonatal Medicine (Dr Hendricks-Munoz), Department of Pediatrics, Children's Hospital of Richmond of VCU, Virginia Commonwealth University School of Medicine, and VCU Center on Health Disparities, Virginia Commonwealth University, Richmond, Virginia; Department of Biostatistics (Dr Thacker), School of Medicine, Virginia Commonwealth University, Richmond, Virginia.

Insights

The COVID-19 pandemic negatively affected clinical trial rates for preterm infant physical therapy. Research teams adapted using telehealth to ensure study continuation and participant safety.

Area of Science:

  • Clinical research methodology
  • Pediatric physical therapy
  • Epidemiology

Background:

  • The COVID-19 pandemic presented unprecedented challenges to global clinical research operations.
  • Disruptions may have influenced study outcomes and data integrity.
  • Understanding pandemic effects is crucial for future research continuity.

Purpose of the Study:

  • To quantify the impact of the COVID-19 pandemic on key clinical trial metrics.
  • Specifically examining recruitment, retention, assessment, and intervention completion rates.
  • Assessing the pandemic's influence on a physical therapy trial for high-risk preterm infants.

Main Methods:

  • Longitudinal clinical trial data were analyzed.
  • Data spanned three periods: pre-pandemic, early pandemic, and peak pandemic (February 2019 - November 2021).
  • Key performance indicators including enrollment, retention, assessment completion, and intervention adherence were compared across these periods.

Main Results:

  • The peak pandemic period exhibited the lowest rates for recruitment, retention, assessment, and intervention completion.
  • These findings indicate a significant negative impact of the pandemic on study operations.
  • Despite challenges, the study successfully transitioned to telehealth.

Conclusions:

  • The COVID-19 pandemic adversely affected clinical trial participation and completion rates.
  • Adaptation to telehealth and hybrid models was essential for study continuation.
  • Research team flexibility, rapid response, and dedication were critical to overcoming pandemic-related obstacles and ensuring participant safety.
Abstract

Related Concept Videos

Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
6.9K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
148
Study Designs in Epidemiology01:20

Study Designs in Epidemiology

Epidemiological study designs are fundamental tools for investigating the distribution, determinants, and control of health conditions in populations. They help researchers understand the relationships between exposures and outcomes, and they broadly fall into two categories: "observational" and "experimental" studies.
Observational studies are those where the researcher does not intervene but rather observes natural variations. They include cross-sectional, cohort, and...
273
Steps in Outbreak Investigation01:18

Steps in Outbreak Investigation

In the ever-evolving field of public health, statistical analysis serves as a cornerstone for understanding and managing disease outbreaks. By leveraging various statistical tools, health professionals can predict potential outbreaks, analyze ongoing situations, and devise effective responses to mitigate impact. For that to happen, there are a few possible stages of the analysis:
152
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
386